Diabetes Research and Clinical Practice
Volume 86, Issue 3 , Pages 247-253 , December 2009

Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study

Received 3 March 2009 ,Revised 24 August 2009 ,Accepted 8 September 2009.

References 

  1. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J. Diabetes Complications. 2003;17(Suppl. 2):11–15
  2. Wu GT, Wang L, Li J, Zhu WZ. Effects of glibenclamide, glimepiride, and gliclazide on ischemic preconditioning in rat heart. Chin. Med. Sci. J. 2007;22(3):162–168
  3. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur. Heart J. 1999;20(March (6)):439–446
  4. Johnsen SP, Monster TBM, Olsen ML, Thisted H, McLaughlin JK, Sorensen HT, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am. J. Ther. 2006;13(2):134–140
  5. Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab. Res. Rev. 2007;23(6):479–484
  6. World Health Organization Model List of Essential Medicines (2007). http://www.who.int/medicines/publications/EML15.pdf, retrieved 6 June 2008.
  7. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30(2):389–394
  8. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. Lancet. 2007;369(9563):750–756
  9. Khalangot M, Tronko M. Primary care diabetes in Ukraine. Primary Care Diabetes. 2007;1:203–205
  10. Tron’ko ND, Khalangot ND, Kravchenko VI, Kul’chinskaia Ia B, Gur’ianov VG, Mis’ko LA. Incidence of proliferative retinopathy and sex-related differences in death rate among patients with diabetes mellitus and sight impairment treated with insulin (according to the data from national diabetic registry). Lik Sprava. 2004;(6):29–32
  11. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest. 2004;34(August (8)):535–542
  12. Henquin JC, Garrino MG, Nenquin M. Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety of glibenclamide: structural requirements and cellular mechanisms. Eur. J. Pharmacol. 1987;141(September (2)):243–251
  13. Gram J, Jespersen J. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients. Am. J. Med. 1991;90:62S–66S
  14. http://www.who.int/whosis/database/life_tables/life_tables_process.cfm?path=whosis,life_tables&language=english, retrieved 16.06.08.
  15. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch. Intern. Med. 2007;167(11):1145–1151
  16. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998) 837–853.
  17. Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E, Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm. Metab. Res. 1996;28(9):419–425
  18. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. 1999;43(3):155–166
  19. Khalangot M, Kravchenko V, Tronko M, Vaiserman A. Assessment of current insulin usage in type 2 diabetics according to diabetes type distribution among insulin-treated patients in Ukraine. Diabetol. Croatica. 2007;36:15–21
  20. Raccah D. Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49: 930–936. Diabetologia. 2007;50(5):1109–1110
  21. Doro P, Benko R, Kosik E, Matuz M, Toth K, Soos G. Utilization of oral antihyperglycaemic drugs over a 7-year period (1998–2004) in a Hungarian population and adherence to drug therapy. Eur. J. Clin. Pharmacol. 2005;61(12):893–897
  22. Lub R, Denig P, van den Berg PB, Hoogenberg K, de Jong-van den Berg LT. The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus. Br. J. Clin. Pharmacol. 2006;62(6):660–665
  23. World Health Statistics (2007). http://www.who.int/healthinfo/statistics/en/, retrieved 16.06.08.
  24. Khalangot M. Current practice of insulin and oral hypoglycaemic agents treatment of diabetes mellitus type 2 patients according to diabetes mellitus register data analysis in the city of Donetsk, Ukraine. Primary Care Diabetes. 2007;1(December (4)):224
  25. M.D. Khalangot, Epidemiologic characteristics of diabetes mellitus type 1 and 2 according to data from national population-based patient register, Manuscript, Thesis for the Degree of Doctor of Medical Sciences, V.P. Komisarenko Institute of Endocrinology and Metabolism AMS of Ukraine, Kiev, 2009.

PII: S0168-8227(09)00380-5

doi: 10.1016/j.diabres.2009.09.008

Diabetes Research and Clinical Practice
Volume 86, Issue 3 , Pages 247-253 , December 2009

Article Tools

* Image Usage & Resolution